Regeneron Pharmaceuticals, Inc. (REGN) Company Bio
Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.
REGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Regeneron Pharmaceuticals Inc. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 53th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:
The company's debt burden, as measured by earnings divided by interest payments, is 108.12; that's higher than 96.23% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than just 10.66% of the free cash flow producing stocks we're observing.
REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.49% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
HRC, ENSG, RSCF, CBPO, and ACIU can be thought of as valuation peers to REGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The Atopic Dermatitis Market analysis report is a competent and deep analysis of the present situation and challenges. It also makes available analysis of market size, shares, growth, segmentation, revenue projection (USD Mn), and regional study till 2026. The market
Sanofi (SNYNF) and Regeneron have announced positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.The trial compared Libtayo monotherapy to platinum-doublet chemotherapy in patients whose tumor cells expressed PD-L1, including those whose cancers had confirmed PD-L1 expression of ≥50%.Lung cancer is the leading cause of cancer death worldwide, with more than 2.2 million new cases expected globally in 2020. Approximately 85% of all lung cancers are NSCLC, and an estimated 25% to 30% of these cases are expected to test positive for PD-L1 in ≥50% of tumor cells.“In new analyses presented at ESMO, L...